BRIEF — Tax reforms persuade Amgen to pick US site for biomanufacturing plant

US drugmaker Amgen has opted to go stateside with the location of a facility that it calls a ‘next-generation biomanufacturing plant’.

Amgen already has one such facility in Singapore but the new plant, the first of its kind in the USA, will be at West Greenwich, Rhode Island, and will manufacture products for the American and global markets.

Due to the incorporation of multiple new technologies into a single facility, the construction time and operating cost of the unit will be around half those of a traditional plant, Amgen says.

A global evaluation of locations was conducted to select the plant’s location, and the company said that the US federal tax reforms had been key to the decision to opt for its 75-acre Rhode Island campus, where it already has a manufacturing facility.